A system biology approach identifies candidate drugs to reduce mortality in severely ill COVID-19 patients
View ORCID ProfileVinicius M. Fava, View ORCID ProfileMathieu Bourgey, View ORCID ProfilePubudu M. Nawarathna, View ORCID ProfileMarianna Orlova, View ORCID ProfilePauline Cassart, View ORCID ProfileDonald C. Vinh, View ORCID ProfileMatthew Pellan Cheng, View ORCID ProfileGuillaume Bourque, View ORCID ProfileErwin Schurr, View ORCID ProfileDavid Langlais
doi: https://doi.org/10.1101/2021.09.14.21262309
Vinicius M. Fava
1Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
2McGill International TB Centre, McGill University, Montreal, QC, Canada
Mathieu Bourgey
3Canadian Centre for Computational Genomics, McGill University, Montréal, QC, Canada
4Department for Human Genetics, McGill University Genome Centre, McGill University, Montréal, QC, Canada
Pubudu M. Nawarathna
3Canadian Centre for Computational Genomics, McGill University, Montréal, QC, Canada
4Department for Human Genetics, McGill University Genome Centre, McGill University, Montréal, QC, Canada
Marianna Orlova
1Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
2McGill International TB Centre, McGill University, Montreal, QC, Canada
4Department for Human Genetics, McGill University Genome Centre, McGill University, Montréal, QC, Canada
Pauline Cassart
1Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
2McGill International TB Centre, McGill University, Montreal, QC, Canada
4Department for Human Genetics, McGill University Genome Centre, McGill University, Montréal, QC, Canada
Donald C. Vinh
1Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
5Division of Infectious Diseases and Division of Medical Microbiology, McGill University Health Center, McGill University, Montreal, Quebec, Canada
Matthew Pellan Cheng
1Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
5Division of Infectious Diseases and Division of Medical Microbiology, McGill University Health Center, McGill University, Montreal, Quebec, Canada
7Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada
Guillaume Bourque
3Canadian Centre for Computational Genomics, McGill University, Montréal, QC, Canada
4Department for Human Genetics, McGill University Genome Centre, McGill University, Montréal, QC, Canada
6McGill University Research Centre on Complex Traits, Montreal, QC, Canada
Erwin Schurr
1Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
2McGill International TB Centre, McGill University, Montreal, QC, Canada
4Department for Human Genetics, McGill University Genome Centre, McGill University, Montréal, QC, Canada
6McGill University Research Centre on Complex Traits, Montreal, QC, Canada
David Langlais
4Department for Human Genetics, McGill University Genome Centre, McGill University, Montréal, QC, Canada
6McGill University Research Centre on Complex Traits, Montreal, QC, Canada
7Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada
Data Availability
The scRNA-seq datasets for the hospitalized COVID-19 patients are available on the European Genome-Phenome Archive, accession number EGAS00001005468. The CITE-seq datasets from healthy controls were retrieved from 10X Genomics. The other healthy controls scRNA-seq datasets were from previously published studies (Lévy et al, JCI 2021). The ATAC-seq and WGBS datasets are available through the International Human Epigenome Consortium (IHEC) data portal (https://epigenomesportal.ca).
Posted September 22, 2021.
A system biology approach identifies candidate drugs to reduce mortality in severely ill COVID-19 patients
Vinicius M. Fava, Mathieu Bourgey, Pubudu M. Nawarathna, Marianna Orlova, Pauline Cassart, Donald C. Vinh, Matthew Pellan Cheng, Guillaume Bourque, Erwin Schurr, David Langlais
medRxiv 2021.09.14.21262309; doi: https://doi.org/10.1101/2021.09.14.21262309
A system biology approach identifies candidate drugs to reduce mortality in severely ill COVID-19 patients
Vinicius M. Fava, Mathieu Bourgey, Pubudu M. Nawarathna, Marianna Orlova, Pauline Cassart, Donald C. Vinh, Matthew Pellan Cheng, Guillaume Bourque, Erwin Schurr, David Langlais
medRxiv 2021.09.14.21262309; doi: https://doi.org/10.1101/2021.09.14.21262309
Subject Area
Subject Areas
- Addiction Medicine (382)
- Allergy and Immunology (699)
- Anesthesia (190)
- Cardiovascular Medicine (2834)
- Dermatology (243)
- Emergency Medicine (427)
- Epidemiology (12538)
- Forensic Medicine (10)
- Gastroenterology (801)
- Genetic and Genomic Medicine (4416)
- Geriatric Medicine (400)
- Health Economics (712)
- Health Informatics (2843)
- Health Policy (1046)
- Hematology (373)
- HIV/AIDS (893)
- Medical Education (413)
- Medical Ethics (114)
- Nephrology (461)
- Neurology (4169)
- Nursing (220)
- Nutrition (615)
- Oncology (2196)
- Ophthalmology (623)
- Orthopedics (254)
- Otolaryngology (317)
- Pain Medicine (265)
- Palliative Medicine (81)
- Pathology (485)
- Pediatrics (1171)
- Primary Care Research (481)
- Public and Global Health (6758)
- Radiology and Imaging (1486)
- Respiratory Medicine (897)
- Rheumatology (430)
- Sports Medicine (368)
- Surgery (472)
- Toxicology (57)
- Transplantation (200)
- Urology (173)